MYL

Mylan N.V.

Healthcare


Presented:11/19/2015
Price:$51.22
Cap:$26.33B
Current Price:$11.84
Cap:$14.13B

Presented

Date11/19/2015
Price$51.22
Market Cap$26.33B
Ent Value$26.42B
P/E Ratio29.27x
Book Value$19.96
Div Yield0%
Shares O/S514.00M
Ave Daily Vol9,002,886
Short Int17.13%

Current

Price$11.84
Market Cap$14.13B
Mylan N.V., is a pharmaceutical company which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceutical products. It operates through the following businesses: Generic Products, Rx Products, Active Pharmaceutical Ingredients, and Access Channels. The Generic Products business provides therapeutic categories, dosage forms and delivery system to help patients. The Rx Products business develops, manufacture and sells prescription medicines to help patients and physicians manage respiratory diseases, severe allergic reactions and psychiatric disorders. The Active Pharmaceutical Ingredients business produces API, the ingredients responsible for medicine's therapeutic effects, and antiretrovirals, the medicines for human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). The Access Channels business provides access to medicines. The company was founded on July 7, 2014 and is headquartered in Potters Bar, United Kingdom.

Publicly traded companies mentioned herein: Abbott Laboratories (ABT), Akorn Inc (AKRX), Mylan NV (MYL), Perrigo Company plc (PRGO), Sanofi SA (SNY), Valeant Pharmaceuticals Intl Inc (VRX)

Highlights

With the Perrigo/ Mylan (MYL) deal falling apart, the presenter sees an opportunity to take a somewhat contrarian long position in shares of MYL at this time (~$51). The collateral damage from Valeant has been severe and multiples in the industry have declined; however, both Perrigo and MYL will likely look to M&A for growth. Given the upside potential he sees for MYL’s EPS and its underleveraged balance sheet (a unique position in specialty pharma), the presenter thinks shares could be worth $65 (10x his 2017 EPS estimate) within 12 months.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.